within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DA13_EritritylTetranitrate;
model EritritylTetranitrate 
   extends Pharmacolibrary.Drugs.ATC.C.C01DA13;

  annotation(Documentation(
    info ="<html><body><p>Eritrityl tetranitrate (ETN) is an organic nitrate vasodilator, historically used in the prophylaxis and treatment of angina pectoris and other ischemic heart diseases. Its clinical use has largely been replaced by other nitrates; it is not commonly used or approved today.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies with detailed parameters such as clearance or volume of distribution for ETN are available. Estimates below are based on general pharmacokinetic properties of organic nitrates.</p><h4>References</h4><ol><li><p>Hannemann, RE, et al., &amp; Starbuck, RR (1981). Digital plethysmography for assessing erythrityl tetranitrate bioavailability. <i>Clinical pharmacology and therapeutics</i> 29(1) 35–39. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1981.6&quot;>10.1038/clpt.1981.6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7006882/&quot;>https://pubmed.ncbi.nlm.nih.gov/7006882</a></p></li><li><p>Rigamonti, AE, et al., &amp; Müller, EE (1999). Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. <i>Metabolism: clinical and experimental</i> 48(2) 176–182. DOI:<a href=&quot;https://doi.org/10.1016/s0026-0495(99)90030-6&quot;>10.1016/s0026-0495(99)90030-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10024078/&quot;>https://pubmed.ncbi.nlm.nih.gov/10024078</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end EritritylTetranitrate;
